ReviewBMC infectious diseases2025
Cupriavidus gilardii infection following heart failure: a case report and literature review.
Review in BMC infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- First case report of concurrent infection with Cupriavidus gilardii and Yarrowia lipolytica following esophageal stenosis resection and anastomosis in a newborn.BMC infectious diseases · 2026Article
- Clinical Management of SevereInfectious disease reports · 2026Article
- Challenge ofTranslational pediatrics · 2025Article
- Severe pneumonia due toFrontiers in medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundCupriavidus gilardii is a species of the genus Cupriavidus. Knowledge about the pathogenic characteristics of Cupriavidus gilardii is limited, especially cardiac infection with this bacterium has not been reported. CASE PRESENTATION: We encountered a case of pulmonary infection after myocardial infarction and heart failure. The initial empirical treatment with meropenem was ineffective. After cultured Cupriavidus gilardii, cefoperazone sulbactam and minocycline were used, and the infection and heart failure was improved for few days. Unfortunately, the patient eventually died of heart failure exacerbated by infection with Staphylococcus Epidermidis.
conclusionMeropenem has a limited therapeutic effect on this bacterium. Monitoring heart function and selecting effective antibiotics are crucial for improving the prognosis of patients suffered from heart disease and Cupriavidus gilardii infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.